Company news

Praxis Precision Medicines, Inc. news in 2025

Praxis Precision Medicines, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

December 28, 2025

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

December 10, 2025

Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy

December 8, 2025

Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies

December 7, 2025

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

December 3, 2025

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

December 3, 2025

Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting

November 23, 2025

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

November 19, 2025

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results

November 4, 2025

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

November 4, 2025

Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback

November 3, 2025

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

October 15, 2025

Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor

October 15, 2025

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

October 9, 2025

ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update

September 29, 2025

Praxis Precision Medicines to Participate in September Investor Conferences

September 3, 2025

Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline

August 24, 2025

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 3, 2025

Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine

August 3, 2025

Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results

July 28, 2025

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies

July 16, 2025

Praxis Precision Medicines to Participate in Upcoming Conferences

May 19, 2025

Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event

May 4, 2025

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 1, 2025

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

April 7, 2025

Praxis Precision Medicines to Participate in Upcoming April Conferences

April 2, 2025

Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting

March 23, 2025

Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences

March 3, 2025

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

February 27, 2025

Praxis Precision Medicines to Present at Two February Investor Conferences

February 2, 2025

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

January 11, 2025

Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference

January 5, 2025

Calls in 2025

Decks in 2025